DNAPRINT ANNOUNCES FILING OF 8-K
stocktribe.com---Dallas, TX---Calgary, AB
SARASOTA, FL., Nov. 3, 2000 –DNAPrint genomics, Inc. (currently traded through the Pink Sheets under ticker symbol: ‘DNAP’) today announced that it has filed a complete form 8-k with the Securities and Exchange Commission (SEC) which provides detailed disclosure of the merger with SDE Holdings 1, Inc., including financial disclosures.
"We are pleased to have completed this filing which will facilitate the dissemination of complete information about the Company and its progress," stated Chief Scientific Officer Dr. Tony Frudakis. Dr. Frudakis added, "Upon completion of appropriate regulatory reviews, the Company intends to file its forms to trade on the NASD Bulletin Board.
ABOUT DNAPRINT GENOMICS, INC.
DNAPrint genomics, Inc. provides practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. On October 17th, the Company announced that it merged with a SEC 12g full reporting company, and expects to be trading on the OTC Bulletin Board within 30 days. The 12g merger did not cause the Company any dilution, and the share structure, trading symbol and name will all remain identically as they existed prior to the 12g merger. For more information about the company, please visit www.DNAPrint.com
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint’s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. These and other risk factors are discussed in the Company’s Form 8-k filed with the Securities and Exchange Commission on November 3, 2000. DNAPrint expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
stocktribe.com has not been compensated for this summary, nor do we hold a position in this company.
To unsubscribe, reply to this e-mail with the word "UNSUBSCRIBE" in the subject line.
AI
